EXPERT CONSENSUS. Treatment approaches to patients with neovascular age-related macular degeneration who need frequent intravitreal injections of aflibercept
DOI:
https://doi.org/10.31288/oftalmolzh202218083Abstract
Treatment approaches to patients with neovascular age-related macular degeneration who need frequent intravitreal injections of aflibercept
References
1.Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014; 98:1144-1167. https://doi.org/10.1136/bjophthalmol-2014-305702
2.Lanzetta P, Loewenstein A; Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017; 255:1259-1273. https://doi.org/10.1007/s00417-017-3647-4
3.Giannakaki-Zimmermann H, Ebneter A, Munk MR, et al. Outcomes when switching from a pro re nata regimen to a treat and extend regimen using aflibercept in neovascular age-related macular degeneration. Ophthalmologica 2016; 236:201-206. https://doi.org/10.1159/000452929
4.Mitchell P, Holz FG, Hykin P et al. Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration. Retina 2021; 41:1911-1920. https://doi.org/10.1097/IAE.0000000000003128
5.Wolf S, Holz FG, Hykin P et al. Neovascular age-related macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E): post-hoc analysis of injection intensive (I-I) requirement for patients in the ARIES study. Invest. Ophthalmol. Vis. Sci. 2021; 62(8):423.
6.Guymer RH, Markey CM, McAllister IL et al. Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen. Ophthalmology 2019; 126:723-734. https://doi.org/10.1016/j.ophtha.2018.11.025
7.Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program. Available at: https://www.novartis.com/news/media-releases/novartis-reports-one-year-r.
8.Letter of appeal from Novartis to healthcare providers July 5, 2021. Available at: https://www.dec.gov.ua/wp-content/uploads/farmakonaglyad/letter-of-cauti.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 а
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
